SUPPRESSOR CELLS AND T-CELL SYNERGY IN THE PRIMARY MLR - INTERLEUKIN-2 IS REQUIRED FOR THE MAINTENANCE OF RAT CD8+ SUPPRESSOR CELLS

被引:2
作者
VANSICKLER, JT [1 ]
PICKARD, LL [1 ]
SALOMON, DR [1 ]
机构
[1] UNIV FLORIDA, DEPT MED, DIV NEPHROL HYPERTENS & TRANSPLANTAT, GAINESVILLE, FL 32610 USA
关键词
D O I
10.1016/0008-8749(91)90312-Y
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The requirements for maintenance of allospecific CD8+ Ts cells generated in the rat primary MLR were investigated. Allospecific CD8+ Ts cells rapidly lose their activity over 72 hr in secondary culture with media alone, whereas low concentrations of rIL2 (<1 U/ml) are able to maintain potent CD8+ Ts cell activity. This Ts cell activity is maintained at rIL-2 concentrations which do not result in significant cell proliferation. Therefore, cell proliferation per se is not a requirement to maintain Ts cell activity, although the CD8+ Ts cells can proliferate to rIL2 in a concentration-dependent manner. An anti-IL-2 receptor monoclonal antibody significantly inhibited the maintenance of Ts cell activity. Two-color flow cytometric analysis demonstrated that Ts cells cultured in rIL-2 maintain upregulation of their high-affinity IL-2 receptor. Although allospecific Ts cells maintained in secondary culture with rIL-2 for 48 hr maintained antigen specificity, there is also the induction of an antigen-nonspecific population. After 168 hr in secondary culture the Ts cells have lost allospecificity, although Ts activity can be maintained with rIL2 in continuous culture for up to 4 weeks. © 1991.
引用
收藏
页码:390 / 401
页数:12
相关论文
共 37 条
[1]  
AUNE TM, 1989, J IMMUNOL, V142, P3731
[2]   FUNCTION AND MIGRATION OF SUPPRESSOR LYMPHOCYTES FROM CYCLOSPORINE-TREATED HEART GRAFT RECIPIENTS [J].
BORDESAZNAR, J ;
KUPIECWEGLINSKI, JW ;
DUARTE, AJS ;
MILFORD, EL ;
STROM, TB ;
TILNEY, NL .
TRANSPLANTATION, 1983, 35 (02) :185-190
[3]  
BUCY RP, 1986, J IMMUNOL, V137, P809
[4]  
BURDICK JF, 1988, KIDNEY TRNASPLANT RE, P127
[5]   PROPHYLACTIC USE OF A MONOCLONAL-ANTIBODY (33B3.1) DIRECTED AGAINST INTERLEUKIN-2 RECEPTOR FOLLOWING HUMAN RENAL-TRANSPLANTATION [J].
CANTAROVICH, D ;
LEMAUFF, B ;
HOURMANT, M ;
PEYRONNET, P ;
JACQUES, Y ;
BOEFFARD, F ;
HIRN, M ;
SOULILLOU, JP .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1988, 11 (02) :101-106
[6]  
DEPPER JM, 1983, J IMMUNOL, V131, P690
[7]   ANTI-INTERLEUKIN-2 RECEPTOR MONOCLONAL-ANTIBODIES SPARE PHENOTYPICALLY DISTINCT T-SUPPRESSOR CELLS INVIVO AND EXERT SYNERGISTIC BIOLOGICAL EFFECTS [J].
DISTEFANO, R ;
MOUZAKI, A ;
ARANEDA, D ;
DIAMANTSTEIN, T ;
TILNEY, NL ;
KUPIECWEGLINSKI, JW .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (06) :1981-1986
[8]  
DORF ME, 1984, ANNU REV IMMUNOL, V2, P127, DOI 10.1146/annurev.iy.02.040184.001015
[9]  
DUARTE AJS, 1982, J IMMUNOL, V128, P580
[10]   A 2ND HUMAN INTERLEUKIN-2 BINDING-PROTEIN THAT MAY BE A COMPONENT OF HIGH-AFFINITY INTERLEUKIN-2 RECEPTORS [J].
DUKOVICH, M ;
WANO, Y ;
THUY, LTB ;
KATZ, P ;
CULLENS, BR ;
KEHRL, JH ;
GREENE, WC .
NATURE, 1987, 327 (6122) :518-522